As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers. Spherix Global Insights ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026. Novo ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — ...

If you are wondering whether Novo Nordisk is still worth buying after its rollercoaster run, you are not alone and this article is going to walk through what the current price really implies. Despite ...

These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo ...

Ozempic has become a phenomenon, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. With ...

Objectives In patients with chronic obstructive pulmonary disease (COPD), severe exacerbations (ECOPDs) impose significant morbidity and mortality. Current guidelines emphasise using ECOPD history to ...